MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for inflammatory diseases using Nanobody technology. Its pipeline consists of Nanobody-based candidates directed at relevant immune pathways, with intended applications in hidradenitis suppurativa and other inflammatory skin and joint diseases. The company is publicly listed on NASDAQ.

The work spans Nanobody technology, immunology and clinical-stage drug development, with therapeutic focus areas in dermatology and rheumatology. Programmes are aimed at conditions with significant unmet medical need, and the company's stated objective is to transform treatment outcomes in inflammatory diseases.

Alongside its pipeline, MoonLake Immunotherapeutics supports commercialization and go-to-market decision-making through data and analytics, assessing patient and prescriber patterns and market coverage. Company updates are published through investor relations. Further information is available at https://moonlaketx.com/.